Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome.
Extensive studies have been conducted to determine the pathogenesis of the adult respiratory distress syndrome (ARDS) by investigating the role of complement, a mediator of inflammation. Complement activation products have been detected in blood samples from patients during ARDS. However, the individual complement components that have been assessed only indicated generalized inflammation, and none could unequivocally discriminate the onset of this acute inflammatory lung injury. In this two-year prospective study of 87 septic patients, 22 of whom developed ARDS (25%), we determined complement activation by quantifying the terminal complement complex (TCC), C5b-9. The TCC is a stable complement by-product formed following activation of either the classical or alternative pathways. Our results show that plasma TCC concentrations increased an average of 110% (p = 0.002) two days prior to the onset of ARDS and also transiently increased an average of 45% (p = 0.01) immediately preceding its resolution. Furthermore, plasma TCC concentrations were a more sensitive measure of this acute inflammatory lung injury than levels of C3a desarginine, C4a desarginine, C5a desarginine, and total hemolytic complement activity. We conclude that a temporal association exists between accentuated formation of plasma TCC and the development and also resolution of septic ARDS. Therefore, we suggest that researchers include plasma TCC concentrations in clinical studies when they could use a potential early indicator for ARDS.
Langlois
P F
PF
Department of Immunology/Microbiology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois.
Gawryl
M S
MS
D003167:Complement Activation; D003176:Complement C3 / Q000031:analogs & derivatives / Q000032:analysis; D015926:Complement C3a / Q000031:analogs & derivatives*; D003181:Complement C4 / Q000031:analogs & derivatives / Q000032:analysis; D015934:Complement C4a; D003182:Complement C5 / Q000031:analogs & derivatives / Q000032:analysis; D015937:Complement C5a, des-Arginine; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D007239:Infections / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012128:Respiratory Distress Syndrome / Q000175:diagnosis* / Q000276:immunology
D003176:Complement C3; D003181:Complement C4; D003182:Complement C5; D015937:Complement C5a, des-Arginine; D015938:Complement Membrane Attack Complex; C044541:complement C3a, des-Arg-(77)-; C051066:complement C4a, des-Arg; D015926:Complement C3a; D015934:Complement C4a; D003165:Complement System Proteins